Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia

François Guilhot, Rüdiger Hehlmann

Blood blood.2024026311.

https://doi.org/10.1182/blood.2024026311

Published: 2024

Journal Articles

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Blood (2023) 142 (Supplement 1): 4539.

https://doi.org/10.1182/blood-2023-180730

Published: 2023

Journal Articles

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Blood (2023) 142 (Supplement 1): 446.

https://doi.org/10.1182/blood-2023-182792

Published: 2023

Journal Articles

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1533.

https://doi.org/10.1182/blood-2023-184745

Published: 2023

Journal Articles

Help for Ukrainian Hematology Patients (HUP) - a Global Initiative Supporting the Establishment of Hematology Centers and Hematopoietic Cell Transplantation Programs in a Time of War

Blood (2023) 142 (Supplement 1): 264.

https://doi.org/10.1182/blood-2023-185883

Published: 2023

Journal Articles

Benefit of TKI-Treatment in CML after Failing Molecular or Cytogenetic Milestones

Rüdiger Hehlmann, Michael Lauseker, Andreas Hochhaus, Susanne Saussele

Blood (2023) 142 (Supplement 1): 4535.

https://doi.org/10.1182/blood-2023-172484

Published: 2023

Journal Articles

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Blood (2022) 140 (Supplement 1): 2126–2129.

https://doi.org/10.1182/blood-2022-157684

Published: 2022

Journal Articles

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Blood (2022) 140 (Supplement 1): 1501–1503.

https://doi.org/10.1182/blood-2022-169324

Published: 2022

Journal Articles

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Blood (2022) 140 (Supplement 1): 947–949.

https://doi.org/10.1182/blood-2022-159412

Published: 2022

Journal Articles

Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

Michael Mauro, Ronald Paquette, Rüdiger Hehlmann, Loretta A. Williams, Stuart L. Goldberg, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S. DeGutis, Ali McBride, Lori Parsons, Monica Z. Montelongo, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 9624–9625.

https://doi.org/10.1182/blood-2022-163080

Published: 2022

Journal Articles

Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study

Jorge E. Cortes, Stuart L. Goldberg, Ronald Paquette, Loretta A. Williams, Rüdiger Hehlmann, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S. DeGutis, Ali McBride, Lori Parsons, Monica Z. Montelongo, Michael Mauro

Blood (2022) 140 (Supplement 1): 3902–3903.

https://doi.org/10.1182/blood-2022-163063

Published: 2022

Journal Articles

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Blood (2019) 134 (Supplement_1): 666.

https://doi.org/10.1182/blood-2019-127127

Published: 2019

Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

Blood (2019) 134 (Supplement_1): 495.

https://doi.org/10.1182/blood-2019-130043

Published: 2019

Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study

Blood (2018) 132 (Supplement 1): 460.

https://doi.org/10.1182/blood-2018-99-112119

Published: 2018

Journal Articles

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Rüdiger Hehlmann, MD, Michael Lauseker, PhD, Susanne Saussele, MD, Markus Pfirrmann, Stefan W. Krause, MD, Hans-Jochem Kolb, MD, Andreas Neubauer, MD, Dieter K. Hossfeld, Christoph Nerl, MD, Alois Gratwohl, MD, Gabriela M. Baerlocher, Dominik Heim, MD, Tim Henrik Bruemmendorf, Alice Fabarius, PhD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martin C. Müller, MD, Sabine Jeromin, PhD, Ulrike Proetel, PhD, Katharina Kohlbrenner, PhD, Astghik Voskanyan, PhD, Sébastien Rinaldetti, Wolfgang Seifarth, PhD, Birgit Spiess, Leopold Balleisen, MD, Maria E Goebeler, MD, Mathias Hänel, MD, Anthony D. Ho, MD, J Dengler, C Falge, Lothar Kanz, MD, Claus-Henning Köhne, MD, PhD, Andreas Burchert, MD, Michael Kneba, MD PhD, Frank Stegelmann, MD, C Köhne, Hans-Walter Lindemann, C Waller, Michael Pfreundschuh, MD, Karsten Spiekermann, Wolfgang E Berdel, MD, L Müller, Matthias Edinger, MD, Jiri Mayer, Prof, MD SCs, Dietrich W Beelen, MD PhD, Martin Bentz, MD, Hartmut Link, MDPhD, Bernd Hertenstein, MD, R Fuchs, Martin Wernli, MD, F Schlegel, Rudolph Schlag, M de Wit, Lorenz Trümper, MD, H Hebarth, M Hahn, Jörg Thomalla, MD, Christof Scheid, MD, Philippe Schafhausen, MD, Walter Verbeek, MD, Michael J. Eckart, MD, Winfried Gassmann, MD PhD, Antonio Pezzutto, MD, Michael Schenk, Peter Brossart, MD, Thomas Geer, MD, Stephan Bildat, E Schäfer, Andreas Hochhaus, MD, Joerg Hasford

Blood (2017) 130 (Supplement 1): 897.

https://doi.org/10.1182/blood.V130.Suppl_1.897.897

Published: 2017

Journal Articles

Cytogenetic and Molecular Responses after 2 Years of Tyrosine Kinase Inhibitor (TKI) Treatment in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Jorge E. Cortes, MD, Stuart L. Goldberg, MD, Mauricette Michallet, MD PhD, Rüdiger Hehlmann, MD, Bengt Simonsson, MD, Michael J. Mauro, MD, Loretta A. Williams, PhD MSN, BSN, BA, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Ginny P Sen, MPH, Aimee Foreman, MA, Srikanth Gajavelli, MD, Carlo Gambacorti-Passerini, MD

Blood (2017) 130 (Supplement 1): 2894.

https://doi.org/10.1182/blood.V130.Suppl_1.2894.2894

Published: 2017

Journal Articles

Imatinib (IM) in Combination with Hydroxyurea Showed Significantly Lower Major Molecular Response Rates at 6 Months but Similar MMR at 18 Months in Patients with CML1st CP Compared to IM Alone. Final Results of the CML2004 Study. NCT 02480608

Thoralf Lange, MD, Rainer Krahl, PhD, Ulrich von Grünhagen, MD, Haifa Kathrin Al-Ali, Schwarzer Andreas, MD, Kathleen Jentsch-Ulrich, MD, Claudia Spohn, MD, Volker Lakner, MD, Michael Assmann, MD, Christian Junghanss, MD, Markus Pfirrmann, Arthur Gil, PhD, Rüdiger Hehlmann, MD, Michael W. Deininger, MD PhD, Dietger Niederwieser, MD

Blood (2017) 130 (Supplement 1): 1615.

https://doi.org/10.1182/blood.V130.Suppl_1.1615.1615

Published: 2017

Journal Articles

Prognostic relevance of CCAs/Ph − in CML settled

Rüdiger Hehlmann

Blood (2017) 130 (19): 2046–2047.

https://doi.org/10.1182/blood-2017-09-804054

Published: 2017

Journal Articles

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

Blood (2016) 128 (22): 1066.

https://doi.org/10.1182/blood.V128.22.1066.1066

Published: 2016

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Switching Patterns during the First 12 Months in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Stuart Goldberg, MD, Mauricette Michallet, MD PhD, Rudiger Hehlmann, MD, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Aimee Foreman, Brian Calimlim, Ron Paquette, MD, Bengt Simonsson, MD, Carlo Gambacorti, MD PhD, Jorge E. Cortes, MD, Aleksandra Zagorska, Yuanxin Rong, Michael J. Mauro, MD

Blood (2016) 128 (22): 937.

https://doi.org/10.1182/blood.V128.22.937.937

Published: 2016

NARROW

Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Help for Ukrainian Hematology Patients (HUP) - a Global Initiative Supporting the Establishment of Hematology Centers and Hematopoietic Cell Transplantation Programs in a Time of War

Benefit of TKI-Treatment in CML after Failing Molecular or Cytogenetic Milestones

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Cytogenetic and Molecular Responses after 2 Years of Tyrosine Kinase Inhibitor (TKI) Treatment in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Imatinib (IM) in Combination with Hydroxyurea Showed Significantly Lower Major Molecular Response Rates at 6 Months but Similar MMR at 18 Months in Patients with CML1st CP Compared to IM Alone. Final Results of the CML2004 Study. NCT 02480608

Prognostic relevance of CCAs/Ph − in CML settled

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

Tyrosine Kinase Inhibitor (TKI) Switching Patterns during the First 12 Months in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only